EASI p-EASI: Predicting Disease Severity in Patients with Atopic Dermatitis Treated with Tralokinumab.

Olydam, Jill I; de Wijs, Linde E M; Dik, Willem A; Røpke, Mads A; Da Rosa, Joel Correa; Hijnen, Dirk Jan

Olydam, Jill I; de Wijs, Linde E M; Dik, Willem A; Røpke, Mads A; Da Rosa, Joel Correa; Hijnen, Dirk Jan.

Afiliación

Olydam JI; Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
de Wijs LEM; Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Dik WA; Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Røpke MA; Department of Clinical Pharmacology, LEO Pharma A/S, Ballerup, Denmark.
Da Rosa JC; Department of Biostatistics, The Rockefeller University Hospital, The Rockefeller University, New York, New York, USA.
Hijnen DJ; Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: d.hijnen@erasmusmc.nl.

J Invest Dermatol ; 142(12): 3335-3337.e1, 2022 12.

Article en En | MEDLINE | ID: mdl-35843313

Asunto(s)

Dermatitis Atópica; Humanos; Dermatitis Atópica/diagnóstico; Dermatitis Atópica/tratamiento farmacológico; Anticuerpos Monoclonales/uso terapéutico; Índice de Severidad de la Enfermedad; Resultado del Tratamiento

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dermatitis Atópica Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Invest Dermatol Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google